Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
460-03-007 ISMRM Abstract

Whole-tumor histogram analysis of quantitative synthetic MRI to identify HER2 zero-, low-, and over-expressing breast cancer

Primary: Body - Breast
Secondary: Acquisition & Reconstruction - Quantitative Imaging: relaxometry, multi-parametric, MR Fingerprinting, and synthetic MRI
460-03-007 · Image Classification for Breast Cancer · Tuesday, 12 May, 1:40 PM–2:35 PM · Digital Posters Row A
Keywords: MR Fingerprinting/Synthetic MR Breast cancer Histogram Analysis Human epidermal growth factor receptor 2
Accepted
Ting Zhan 1, Wenjie Liu1, Xinyi Liu1, Fengyuan Luo1, Jiankun Dai2, YinPing Leng1, Lianggeng Gong1,3,4
1The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, China
2MR Research, Beijing, China
3The Second Affiliated Hospital of Nanchang University, Nanchang, China
4Intelligent Medical Imaging of Jiangxi Key Laboratory, Nanchang, China
Presenting Author: Ting Zhan

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Sung, H., J. Ferlay, R.L. Siegel, et al., Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 2021. 71(3): p. 209-249.DOI: 10.3322/caac.21660 [doi]
2. Banerji, U., C.M.L. van Herpen, C. Saura, et al., Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol, 2019. 20(8): p. 1124-1135.DOI: 10.1016/s1470-2045(19)30328-6 [doi]
3. Modi, S., H. Park, R.K. Murthy, et al., Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study. J Clin Oncol, 2020. 38(17): p. 1887-1896.DOI: 10.1200/jco.19.02318 [doi]
4. Ji, S., D. Yang, J. Lee, et al., Synthetic MRI: Technologies and Applications in Neuroradiology. J Magn Reson Imaging, 2022. 55(4): p. 1013-1025.DOI: 10.1002/jmri.27440 [doi]
5. Eun, N.L., D. Kang, E.J. Son, et al., Texture Analysis with 3.0-T MRI for Association of Response to Neoadjuvant Chemotherapy in Breast Cancer. Radiology, 2020. 294(1): p. 31-41.DOI: 10.1148/radiol.2019182718 [doi]
6. Li, Q., Q. Xiao, M. Yang, et al., Histogram analysis of quantitative parameters from synthetic MRI: Correlations with prognostic factors and molecular subtypes in invasive ductal breast cancer. Eur J Radiol, 2021. 139: p. 109697.DOI: 10.1016/j.ejrad.2021.109697 [doi]
7. Xu, A., X. Chu, S. Zhang, et al., Development and validation of a clinicoradiomic nomogram to assess the HER2 status of patients with invasive ductal carcinoma. BMC Cancer, 2022. 22(1): p. 872.DOI: 10.1186/s12885-022-09967-6 [doi]
8. Bian, X., S. Du, Z. Yue, et al., Potential Antihuman Epidermal Growth Factor Receptor 2 Target Therapy Beneficiaries: The Role of MRI-Based Radiomics in Distinguishing Human Epidermal Growth Factor Receptor 2-Low Status of Breast Cancer. J Magn Reson Imaging, 2023. 58(5): p. 1603-1614.DOI: 10.1002/jmri.28628 [doi]
9. Guo, Y., X. Xie, W. Tang, et al., Noninvasive identification of HER2-low-positive status by MRI-based deep learning radiomics predicts the disease-free survival of patients with breast cancer. Eur Radiol, 2024. 34(2): p. 899-913.DOI: 10.1007/s00330-023-09990-6 [doi]
10. Ramtohul, T., L. Djerroudi, E. Lissavalid, et al., Multiparametric MRI and Radiomics for the Prediction of HER2-Zero, -Low, and -Positive Breast Cancers. Radiology, 2023. 308(2): p. e222646.DOI: 10.1148/radiol.222646 [doi]
11. Hou, Y., H. Nitta, and Z. Li, HER2 Intratumoral Heterogeneity in Breast Cancer, an Evolving Concept. Cancers (Basel), 2023. 15(10).DOI: 10.3390/cancers15102664 [doi]
12. Dai, W., O. Navolotskaia, J.L. Fine, et al., Not All HER2-Positive Breast Cancers Are the Same: Intratumoral Heterogeneity, Low-Level HER2 Amplification, and Their Impact on Neoadjuvant Therapy Response. Mod Pathol, 2025. 38(7): p. 100785.DOI: 10.1016/j.modpat.2025.100785 [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/460-03-007